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MnTnHex-2-PyPIncreased understanding of the role of mitochondria under physiological and pathological conditions paral-
lels increased exploration of synthetic and natural compounds able to mimic MnSOD — endogenous mito-
chondrial antioxidant defense essential for the existence of virtually all aerobic organisms from bacteria to
humans. This review describes most successful mitochondrially-targeted redox-active compounds, Mn por-
phyrins and MitoQ10 in detail, and brieﬂy addresses several other compounds that are either catalysts of
O2− dismutation, or its non-catalytic scavengers, and that reportedly attenuate mitochondrial dysfunction.
While not a true catalyst (SOD mimic) of O2
− dismutation, MitoQ10 oxidizes O2
− to O2 with a high rate con-
stant. In vivo it is readily reduced to quinol, MitoQH2, which in turn reduces ONOO− to NO2, producing semi-
quinone radical that subsequently dismutes to MitoQ10 and MitoQH2, completing the “catalytic” cycle. In
MitoQ10, the redox-active unit was coupled via 10-carbon atom alkyl chain to monocationic triphenylpho-
sphonium ion in order to reach the mitochondria. Mn porphyrin-based SOD mimics, however, were designed
so that their multiple cationic charge and alkyl chains determine both their remarkable SOD potency and
carry them into the mitochondria. Several animal efﬁcacy studies such as skin carcinogenesis and UVB-
mediated mtDNA damage, and subcellular distribution studies of Saccharomyces cerevisiae and mouse heart
provided unambiguous evidence that Mn porphyrins mimic the site and action of MnSOD, which in turn con-
tributes to their efﬁcacy in numerous in vitro and in vivo models of oxidative stress. Within a class of Mn por-
phyrins, lipophilic analogs are particularly effective for treating central nervous system injuries where
mitochondria play key role. This article is part of a Special Issue entitled: Antioxidants and Antioxidant Treat-
ment in Disease.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Superoxide (O2−) has a prominent role in oxidative stress and im-
pacts the production of a plethora of other reactive species, such as
H2O2, peroxynitrite (ONOO−), peroxynitrite degradation products
(OH, NO2, CO3−), lipid peroxyl (RO2) and alkoxyl (RO) radicals. Its
one-electron reduction product, H2O2, is a dominant signaling mole-
cule [1]. Endogenous antioxidants maintain reactive species at nano-
molar levels, and any increase results in redox imbalance (oxidativexidants and Antioxidant Treat-
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l rights reserved.stress) [2], which in turn leads to excessive inﬂammatory and immune
responses. The superoxide dismutase family of enzymes is comprised of
MnSOD located in the mitochondrial matrix, and Cu,ZnSOD located in
the mitochondrial intermembrane space, cytosol and extracellular
space. These key enzymes catalyze the dismutation (disproportion-
ation) of superoxide anion radical to hydrogen peroxide and molecular
oxygen [2]. In doing so, they protect cells against oxidative damage and
regulate the cellular concentration of O2− and its reactive progeny under
both physiological and pathological conditions [2]. Mutations in Cu,
ZnSOD have been linked to amyotrophic lateral sclerosis, and deﬁ-
ciency of Cu,ZnSOD has been associated with accelerated aging and
a higher incidence of cancer [3–6]. However, aerobic life without
MnSOD is not sustainable. A substantial body of evidence has been
established by Fridovich and his associates [7,8] that MnSOD is ubiqui-
tous metalloenzyme essential for the survival of all aerobic organisms
from bacteria to humans. It is even found in many anaerobes where it
protects the cell during exposure to aerobic conditions [9]. Cambialistic
enzymes are found in several anaerobic bacteria, such as Propionibacter-
ium shermanii, and have either Mn3+ or Fe3+ at their active site. When
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under micro aerobic conditions, these enzymes have Mn3+ at their ac-
tive site [10]. MnSOD is encoded by a nuclear gene and is transported
across two mitochondrial membranes to the matrix. In humans, this
translocation involves translation of a proenzyme which includes a
24-amino acid N-terminal peptide targeting the protein to the mito-
chondria. In mice, the lack of MnSOD, or the complete elimination of
its expression, causes dilated cardiomyopathy and neurodegenera-
tion leading to early postnatal death. These mice exhibit severe oxida-
tive damage to mitochondria and are also extremely sensitive to
hyperoxia [11,12]. It has been clearly demonstrated that heterozy-
gous MnSOD knock-out mice have a 50% decrease in MnSOD enzyme
activity in all tissues compared to wild-type mice, resulting in an age-
dependent increase in oxidative DNA damage (8-hydroxy-2′-deoxy-
guanosine) in both nucleus and mitochondria.
A critical role of MnSOD under physiological and pathological
conditions has recently been reviewed in details by St. Clair's group
[13,14]. Herein, we brieﬂy summarized the role of MnSOD in general,
and tumorigenesis in particular. The MnSOD enzyme is involved in
maintaining nanomolar, physiological levels of O2− and its progeny.
In a very elegant and comprehensible report by Buettner et al., a
more complex role of MnSOD in establishing cellular redox envi-
ronment and thus biological state of the cell was discussed based
on thermodynamic and kinetic grounds [15,16]. In addition to its
traditional role in controlling levels of O2− via catalysis of O2− dis-
mutation, MnSOD also modulates the accumulation of H2O2 in
cells, most so effecting those O2−-involving reactions whose equi-
librium constant is Kb1, such as the production of superoxide
from mitochondrial respiration at the site of coenzyme Q [15,16].
Moreover, MnSOD inﬂuences the activity of transcription factors
(such as HIF-1α, AP-1, NF-κB and p53) and affects DNA stability: an
example being the action of overexpressed MnSOD on the maspin
(mammary serine protease inhibitor) mRNA in MCF-7 breast cancer
cells that results in decreased invasiveness [17]. Further, overex-
presssion of MnSOD affects the activity of HIF-1α in MCF cells in a bi-
phasic manner: at lower levels of MnSOD, HIF-1α levels are elevated,
but are suppressed at higher MnSOD levels [18]. The biphasic inﬂuence
of MnSOD on activation of HIF-1α is H2O2-dependent, as removal of
peroxides reverses the effect [18]. While the same biphasic behavior
has been observed in IL-1α expression, it has not been observed in
the migration potential of HT-1080 cells [19]. Low levels of MnSOD
are able to drive migration, and higher levels of MnSOD potentiate
the effects. Further, overexpression of MnSOD causes reduction of
AP-1 transcriptional activity in MCF-7 cells, which is mediated through
altered expression of the Jun family of AP-1 subunits [20]. In a DMBA/
TPA skin carcinogenesis model, AP-1 activation was much higher in
normal (non-transgenic) mice than in MnSOD overexpressor (trans-
genic) mice [20]. Overexpression of MnSOD in MCF-7 cells diminishes
NF-κB activity and expression of IL-1 and IL-6, both NF-κB responsive
genes. MnSOD also modulates the transcriptional activity of p53 [21]. Fi-
nally, overexpression of MnSOD impedes aneuploidy in Lck-Bax38/1
mice [22,23]. A recent study byMesquita et al. on the life-span of Sac-
charomyces cerevisiae further emphasizes a vital role of MnSOD in
cell physiology.When yeast was stressed by caloric restriction or cat-
alase inactivation, and H2O2 levels increased above physiological
levels but did not reach toxicity, the yeast tried to adapt via H2O2-in-
duced stress response and upregulated SODs, in particular MnSOD
[24]. Similar hormesis effects are suggested to be operative in aging
[24]. Similarly, the modulation of O2− levels and transcriptional activity
observed with MnSOD were detected with Mn porphyrin-based SOD
mimics (see below, under Mn porphyrins section).
An early report by Oberley (L.W. and T. D.) and Buettner showed
that many tumor types have low levels of MnSOD [25,26], and over-
expression of MnSOD was shown to suppress the tumorigenicity of
human melanoma cells, breast cancer cells, and glioma cells, suggest-
ing that MnSOD is a tumor suppressor gene in a wide variety ofcancers [3–6]. Yet, Hempel et al. have presented data that show in-
creased levels of MnSOD in different tumor types [19]. Additional in-
crease of MnSOD level was found during progression of a tumor to the
metastatic stage in head and neck, pancreatic, gastric, colorectal brain,
and oral squamous cell carcinomas. Such apparently controversial
data likely arise from the differences in the redox status of the tumors
explored (Fig. 1). Tumorigenesis and metastasis are strongly dependent
on the intrinsic levels of reactive species, as well as external factors that
would increase the production of reactive species. A “normal” cell which
has low levels of MnSOD is susceptible to oxidative stress, which in turn
may favor its progression to a tumor cell [19] (Fig. 1). Further, studies
with transgenic mice expressing a luciferase reporter gene under the
control of human MnSOD promoter demonstrate that the levels of
MnSOD in such already transformed cell were reduced prior to the for-
mation of cancer [13,27]. As transformed cell proliferates, it is possible
that it ﬁghts oxidative stress by upregulating MnSOD, which might
result in an imbalance between the superoxide and peroxide
removing enzymes, resulting in turn in increased peroxide levels
[15,19,28,29]. Peroxide would then perpetuate oxidative stress by
affecting a broad array of signaling pathways that promote malig-
nancy and metastasis. The upregulation of NADPH oxidases would
sustain or enhance H2O2 levels. Lower levels of MnSOD were found
in prostate cancer, but an increase in circulating MnSOD positively
correlated with tumor reoccurrence in the form of bone metastases
[30]. Catalase levels are often decreased in a variety of tumors and
expression appears to decrease further with progression of a
metastatic disease [31]. Similar results have been reported for
the Se-based H2O2-scavenging enzymes, glutathione peroxidase,
peroxiredoxin, thioredoxin reductase and selenoprotein P plasma 1
[32–36]. Many malignant properties have been reversed by the co-
expression of catalase [19]. The overexpression of catalase pro-
tected cancer cell from death when cell killing was aimed via
excessive production of peroxide as a consequence of combined
menadione/ascorbate anticancer therapy [37]. Based on such re-
port, MnSOD has been considered as both tumor suppressor and
tumor promoter.
In the initial onset/proliferative stage of a tumor, MnSOD appears to
be a tumor suppressor (Fig. 1). Yet, once tumor progresses to amore ag-
gressive and invasive phenotype andMnSOD is upregulated, the role
of MnSOD is that of an oncogene, sinceMnSOD level positively corre-
lates with enhanced metastasis [19,38]. Further evidence for the role
of MnSOD as an oncogene has been provided by studies showing that
overexpression of MnSOD in aggressive cancers is related to the in-
creased level of H2O2 [19]. However, the increased tumor peroxide
levels that result in enhanced malignancy, might be more accurately
described as arising from a perturbed harmony between the actions
of superoxide- and peroxide-removing enzymes as well as from the
changes in the expression of other H2O2-producing systems such as
NADPH oxidases, and not from the singular action of MnSOD. The im-
pact of MnSOD overexpression on superoxide production from the
electron transport chain, mentioned above, would contribute to
the increased H2O2 production also [16]. Recently a study by St.
Clair's group showed that the suppression and subsequent restora-
tion of MnSOD expression is mediated by p53 and Sp1 [38]. In an
early stage of skin carcinogenesis, MnSOD is suppressed by
decreased Sp1 binding to the MnSOD promoter, which is consistent
with the fact that Sp1 is essential for the basal expression of MnSOD
and basalMnSOD transcription [38]. However, as the tumor progresses
in an environment of high oxidative stress, p53 activity is lost and the
MnSOD levels increase again creating conditions in which cancer cells
survive and undergo metastasis [38]. Both the Sp1 binding to MnSOD
promoter as well as the loss of p53 is likely mediated by the cellular
redox status.
Finally, due to the enhanced oxidative stress, it is possible that the
MnSOD protein expression is upregulated, yet protein inactivated via ox-
idative modiﬁcations, and therefore its metastatic potential suppressed
Fig. 1. A simpliﬁed presentation of the role of MnSOD under physiological and pathological conditions. The possible scenario presented here aims at reconciliation of the dichoto-
mous role of MnSOD as tumor suppressor (antioxidant) or oncogene (pro-oxidant). The differences in these two opposing roles are likely related to the different redox-status of the
cell, primarily to the ratio of the endogenous antioxidants that controls O2−/H2O2 ratio. The common understanding is that cells which have intrinsically lower levels of MnSOD are
under oxidative stress and may eventually transform into cancer cells. Further, when exposure to either single or multiple oxidative insults transforms cells prior to their becoming
malignant, MnSOD levels are low and the cells are consequently under oxidative stress. The impaired redox status would in turn result in higher oxidative damage of biological
targets, nucleic acids included, which would amplify mutations and enforce tumorigenesis. Once the process starts, the oxidative stress is perpetuated and the cell ﬁghts it by upre-
gulation of MnSOD. The reportedly reduced ability of a malignant cell to remove H2O2 [32–36] further perpetuates the oxidative stress, and MnSOD would appear as an oncogene.
Tumor utilizes increased levels of peroxide to signal the activation of transcription factors and upregulation of those proteins (such as HIF-1α, VEGF, NADPH oxidases), which would
maintain its oxidative stress and facilitate its progression and metastasis [1]. The complex role of MnSOD in maintaing the cellular redox status, via both its traditional role and by
modulating cellular production of H2O2, has been elaborated by Buetner et al. [16], while St. Clair's group has recently [38] pointed to the critical role of Sp1 and p53 in early and late
stages of tumorigenesis on the levels of MnSOD expression. — normal cell; — transformed cell; — cancer cell.
(2)
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His-30 is an important amino acid involved in the hydrogen bond net-
work in the catalytic domain of MnSOD. The proteomic analysis of
MnSOD from a medulloblastoma cell line showed the presence of 2-
oxo-histidine in His 30 and 31 residues [19]. Another mechanism of
MnSOD inactivation is nitration of a protein tyrosine residue [39,40]. A
similar observation was recently published with respect to thioredoxin
in a low-grade human prostate cancer tissue: though protein levels
were increased, the thioredoxin activity was reduced [41]. It is therefore
critical that conclusions are always based on both protein expression
and its activity.
In summary, the opposing views of MnSOD as tumor suppressor (an-
tioxidant) or oncogene (pro-oxidant) may possibly be reconciled based
on the differences in the redox status of normal, transformed, tumor
and metastatic cells (Fig. 1). Much remains to be learned about the
role of both MnSOD and its mimics under physiological and patho-
logical conditions. For further discussion, see also the Special Issue
of Anti-Cancer Agents in Medicinal Chemistry, on “SOD enzymes and
their mimics in cancer: pro- vs anti-oxidative mode of action,”
ACAMC, 2011 [14,15,19,28,29].
2. SOD mimics
The essential role of superoxide dismutases in maintaining healthy
metabolism and rescuing diseased cells, the rising awareness of the
key impact of oxidative stress in numerous diseases, and the essential
role of mitochondria in cell metabolism have led to a three-decade
long effort to synthesize SOD mimics, particularly those that target(1)mitochondria. The ﬁrst data appeared in the late 1970s on the ability
of Fe porphyrin, FeTM-4-PyP5+, to catalyze O2− dismutation, via a
two-step process (Eqs. (1) and (2), where M stands for metal) alike
the one operative with SOD enzymes [42]:
It is only logical that the ﬁrst compound studied as an SOD mimic
was a metal complex. With SOD enzymes (FeSOD, MnSOD, NiSOD,
Cu,ZnSOD), the catalysis occurs at the redox active metal site, which
is able to easily accept and donate electrons and thus oxidize and reduce
O2−. Iron porphyrin was the ﬁrst metalloporphyrin explored, as iron
is the active site of numerous enzymes whose functions are redox-
based. The examples are the cyt P450 family of enzymes, nitric oxide
synthases, cyclooxygenases, and prolylhydroxylases. The reason for
utilizing a metalloporphyrin as an active site is the cyclic nature of
the porphyrin ligand which forms a metal complex of extreme sta-
bility, and thus assures the integrity of the metal site. Exploration of
Mn porphyrins followed. Relative to Fe porphyrins, they have been
considered more favorable agents for O2− removal, as they preclude
the release of “free” iron, which could possibly result in a Fenton-
based toxicity. Other metal complexes, such as Mn salen derivatives,
Mn cyclic polyamines,metal corroles,metal salts,metal oxides, Pt nano-
particles and non-metal compounds such as nitrones and nitroxides as
well as natural products, have also been explored for their ability to cat-
alytically remove O2− (Figs. 2 and 3), and were discussed in details
elsewhere [27,43–46]. Among the synthetic compounds, nitrones and
nitroxides are not able to catalytically scavenge superoxide, whereas
they are able to react with peroxynitrite. The oxoammonium cation,
formed during one-electron oxidation of nitroxide, can in turn react
with O2−, completing the “catalytic” cycle. Low-molecular Mn com-
plexes with carboxylates have also been explored, as nature utilizes
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Fig. 2. Chemical structures of mitochondrially-targeted metal based SOD mimics.
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such studies are valuable because most high-molecular weight Mn
complexes could release Mn, when cycling from a stable, higher +3
oxidation state to a less stable lower +2 oxidation state of Mn, during
the two steps of a dismutation process. Among high-molecular weight
metal complexes, cationic Fe and Mn porphyrins bearingmeso cationic
pyridyl substituents, appear to have the highest catalytic rate constant
for O2− dismutation, kcat(O2−). Those compounds, which are substituted
with electron-withdrawing groups on both beta and meso positions of
porphyrin ring (Figs. 2 and 7), have the highest kcat, nearing that of
the enzyme itself. Themost potent is theMn(II)β-octabromo-meso-tet-
rakis(N-methylpyridinium-3-yl)porphyrin, MnBr8TM-3-PyP4+ (Fig. 7,
Table 1), whose log kcat is ≥8.85, while SOD has the log kcat in be-
tween 8.84 and 9.30 [45]. Yet, the complex is unstable as it carries
Mn in a lower +2 oxidation state, which has insufﬁcient charge den-
sity to bind porphyrin ligand strongly enough. With no β-
substituents, the Mn(III) N-alkylpyridylporphyrins are stableN OO. Tempone
Ntroxides
NO. O
O
O
P
PONO
.
O
Mito-Tempol
MitoCarboxyproxyl, Mito-CP
H2N
Fig. 3. Structures of mitochondrially-targcomplexes (even in 36% hydrochloric acid), and have a log kcat rang-
ing from 6.58 to 7.79. A comprehensive overview of different classes
of SOD mimics has been reported recently [44–46].
3. MnSOD mimics
Increased understanding of the role of mitochondria and its en-
zyme, MnSOD, has motivated researchers to explore existing and
new compounds for their ability to enter mitochondria and mimic
MnSOD. This review covers only those compounds that reportedly
possess fair SOD-like properties (are catalysts of O2− dismutation),
or are stoichiometric scavengers of O2−, and for which evidence exists
that they are efﬁcacious in attenuating mitochondrial dysfunction. Mn
porphyrins and MitoQ10 are addressed in this report in detail, as there
is substantial evidence that they accumulate in mitochondria and
possess high rate constants for reaction with O2−. Both types of
compounds bear a cationic charge (shown by Liberman, SkulachevP
O
O
MitoQ10
N
HNOHO
O
HO
O
O
OH
O
Pyrroloquinoline quinone
N
P
NH2
MitoSOXTM Red
eted non-metal based SOD mimics.
Table 1
The log kcat for O2− dismutation, E1/2, metal-centered reduction potential for MIII/MII
redox couple (where M stands for metal) and the lipophilicity of SOD mimics
expressed in terms of their partition between n-octanol and water, log POW. The POW
values for MitoQ10 and CoQ10 relate to distribution between n-octanol and PBS. Some
other compounds that are mentioned in the text, but are not SOD mimics and/or no
data exist on their mitochondrial accumulation, are listed also for comparison, and
are indicated with “⁎”.
Compound E1/2, mV vs NHE log kcat(O2−) log POW
MnT-2-PyP+⁎ −280 4.29
MnTPP+⁎ −270 4.83
MnTBAP3−⁎ −194 3.16
MnBr8TM-3-PyP4+ +468 >8.85
MnTCl5TE-2-PyP4+ +560 8.41
MnTM-2-PyP5+ +220 7.79 −8.16d
MnTE-2-PyP5+ +228 7.76 (cyt c),
7.73 (p.r.)
−7.79d
MnTnHex-2-PyP5+ +314 7.48 −3.84e
MnTnOct-2-PyP5+ +367 7.71 −2.32e
MnTM-4-PyP5+ +60 6.58
MnTDE-2-ImP5+⁎ +346 7.83
FeTE-2-PyP(OH)4+⁎ +215 8.00
MnSalen, EUK-8 −130a 5.78
MnSalen EUK-189 ~−130a 5.78 (0.37 (IC50
~l μM, NBT
assay) [88]
−0.9 [88]
MnSalen, EUK-134 ~−130a 5.78
MnSalen, EUK-207 ~−130a 0.48 (IC50
~l μM, NBT
assay) [88]
−1.41 [88]
MitoQ10 −105 (MitoQ/
UQH.), water
8.30, kox(O2−) 3.44 (37 °C,
n-octanol/PBS [89]
CoQ10 −427 (UQ/UQH.),
aprotic solvents
20.26
Nitroxide, Temponeb +918 [90]
Nitroxide,b
MitoCarboxyproxyl⁎b
+792
(3-carboxyproxyl)
Nitroxide,
Mito-Tempol⁎b
+810
(Tempol)
5.53 (Tempol)
MnMImP3P2+ [72] 6.92 4.78
Mn2+ +850c 6.11 (cyt c),
6.28 (p.r.)
0
SOD enzymes ~+300 8.84–9.30
a Estimate; no effect of structural modiﬁcations on the SOD-like activity of com-
pounds of EUK series has been observed. Thus, we can safely estimate that all 4 listed
analogs have similar E1/2 and kcat.
b The one-electron reduction potentials refer to RNO+/RNO redox couple which is
involved in the reaction of nitroxides with superoxide and peroxynitrie [46].
c Oxidation potential only, MnIII/MnII redox couple is irreversible.
d Calculated according to the equation log POW=12.207×Rf–8.521;
e Determined experimentally using n-butanol and water biphasic system (PBW) and
converted to log Pow according to the equation lop POW=1.55×PBW–0.54 [91,92].
When references are not indicated, the data are taken from refs [44–46].
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dria), lipophilic entity and a redox-active unit [51–53]. Singly-
charged MitoQ10 is more lipophilic than either of the pentacationic
Mn porphyrins studied; it seems that, at least in part, the multiple
charge of Mn porphyrins compensates for their much lower lipophi-
licity. Mn cyclic polyamine-based SOD mimics and the most potent
compounds within the class of redox-active corroles lack positive
charge or are anionic compounds, respectively; their mitochondrial
accumulation would thus be disfavored [46,54]. No evidence has
yet been provided that these compounds reach mitochondria.3.1. MnSOD-plasmid liposome gene
The natural way to compensate for MnSOD is to use MnSOD itself
in a bioavailable form — MnSOD-plasmid liposome gene. Such ther-
apy has been shown to decrease irradiation-induced lipid peroxida-
tion of the mouse esophagus [55].3.2. The attachment of mitochondria-targeted amino acid sequence to a
Mn porphyrin-based SOD mimic
Asayama et al. attached amitochondria-targeted amino acid sequence
to a Mn porphyrin-based SOD mimic, MnTM-4-PyP5+ (Fig. 2) [56]. By
using the pH-sensitive aminated poly(L-histidine) drug carrier for intra-
cellular delivery, the new conjugate recovered the viability of lipo-
polysaccharide (LPS)-stimulated macrophage RAW 264.7 cells.
3.3. Pyrroloquinoline quinone (PQQ)
PQQ (Fig. 3) is a water-soluble redox cycling orthoquinone, a nu-
trient widely distributed in nature. It serves as a non-covalently bound
redox cofactor in a series of bacterial quinoprotein dehydrogenases
and has been explored for treatment of mitochondrial disorders [57].
In the presence of reductants, PQQ scavenges ROS in bacteria [58].
PQQprotects isolated livermitochondria fromoxidative damage, via su-
peroxide scavenging, and was neuroprotective in a rodent stroke
model where its action was assigned to peroxynitrite scavenging
[57–63]. PQQ also reduces myocardial infarct size, improves cardiac
function, and reduces lipid peroxidation as measured by malondial-
dehyde levels [64,65].
3.4. MnSalens
While not signiﬁcantly efﬁcacious in a cellular model of ataxia
telangiectasia, MnSalen, EUK-8 (Fig. 2) was very efﬁcacious in the pro-
tection of the MnSOD-knock out yeast Cryptococcus neoformans against
heat-mediated injury [66]. Neither cationic nor anionic Mn porphyrins
were efﬁcacious. Also, Tempol and MnCl2 lacked efﬁcacy. EUK-8 is a
fairly unstable complex and loses Mn in the presence of EDTA [67].
Therefore, in vivo, MnSalen perhaps serves as aMn transporter intomi-
tochondria. Cationic Mn(III) N-alkylpyridylporphyrin complexes are
too strong to release manganese. MnTBAP3− carries a triple negative
charge and thus cannot easily reach mitochondria. Furthermore, it is
too stable to release Mn there, and is not SOD mimic in its own right
[68]. Data on C. neoformans justify further exploration of MnSalen
derivatives. Irradiated astrocytes have been shown to develop mito-
chondrial abnormalities attenuated in a dose-dependent manner by
EUK-134. Vorotnikova et al. showed that EUK-207 and EUK-189 in-
hibit radiation-induced apoptosis in bovine adrenal endothelial
cells [69]. A study on life-span extension and rescue of spongiform en-
cephalopathy in MnSOD−/−mice showed that EUK-8 mimics MnSOD;
yet, that report has been questioned by Keaney et al. [70,71].
3.5. MnMImP3P
2+
The Mn(III) porphyrin, MnMImP3P2+, depicted in Fig. 2, report-
edly targets mitochondria [72]. When compared to its fully ethylated
tetraimidazolyl analogMnTDE-2-ImP5+, the compound has only one
imidazolium ring fully methylated, and thus carries 2 instead of
8methyl groups. Consequently, MnMImP3P2+ bears only 2+ instead
of 5+ total charges, has therefore reduced antioxidant potency, but
increased lipophilicity relative to MnTDE-2-ImP5+ (Table 1). The in-
ferior SOD-like activity of MnMImP3P2+ is at least in part compen-
sated by its fair lipophilicity (log POW=4.78), which in turn favors
its mitochondrial accumulation.
3.6. Nitroxides
Nitroxides (Fig. 3) are weak SOD mimics [46]; their SOD activity
increases with a pH drop due to their high reactivity with protonated
superoxide, HO2; the RNO/RNO+ redox couple is involved [46]. Nitr-
oxides, RNO can be oxidized to oxoammonium cation, RNO+ with
ONOO− (Table 1), which in turn rapidly reacts with O2− regenerating
RNO; thus, the catalytic removal of O2−may be coupled to the reaction
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RNOH, which reportedly acts as an antioxidant [73]. The lipophilic keto
analogs, tempone and oxazolidine-5-doxylstearate (but not hydrophilic
tempol), are reduced by mitochondria of intact cells, which indicates
the ability of nitroxide to reach these cellular components. While
nitroxides are uncharged, nitrones such as PBN carry an anionic charge.
Therefore, PBN may localize in mitochondria only after reacting with
free radicals, thereby losing its anionic charge [74]. 5,5-dimethyl-1-
pyrroline-1-oxide, DMPO, a spin trapping agent, reportedly enters
mitochondria, where it is reduced by the electron-transport chain
of mitochondria of synaptosomes [75].
3.7. Mangafodipir
A Mn complex with dipyridoxyl diphosphate (Fig. 2), a MRI contrast
agent for liver and cardiac imaging, has been shown to improve contrac-
tile function and reduce enzyme release in rat heart tissue during reoxy-
genation, and could be used as a viability marker in patients with
myocardial infarction. It has also been shown to reduce mitochondrial
damage by reducing reactive species, presumably mimicking superoxide
dismutase [76], catalase and glutathione reductase [77].
3.8. Mitochondria-targeted peptide
Other compounds that possess the ability to scavenge reactive
species, but that have no SOD-like activity, have also been developed.
An example is the mitochondrially-targeted peptide that contains
dimethyltyrosine unit (Dmt), which reportedly scavenges reactive
species [78,79]. The unique feature of SS-02 (H-Dmt-D-Arg-Phe-Lys-
NH2) is its alternating aromatic–cationic structural motif, where aro-
matic residues (Dmt and Phe) alternate with basic residues (Arg and
Lys). This motif allows for intramolecular cation-π interaction be-
tween the electron-rich π ring (Dmt or Phe) and the adjacent cation
(Arg or Lys). The additional methyl groups on Dmt further increase
electron density on the π ring. Cation-π energies are of the same
order of magnitude as hydrogen bonding energies, and the π rings
may shield the cation charge and enhance membrane penetration.
Thus, this aromatic–cationic motif is retained in the design of non-
opioid analogs of SS-02. Reactive nitrogen and halogen species, OH
and RO2/RO [80], are known to target tyrosine, thereby producing
dihydroxyphenylalanine and tyrosine radicals. Tyrosine radicals
would form dityrosine, a reaction that is facilitated by O2− [81]. While
substitution of dimethyltyrosine with phenylalanine resulted in a
loss of antioxidant capacity, the peptide was still able to reduce
ROS generation [78,79]. It must be noted that formation of tyrosine
radical is usually associated with the oxidative damage of protein
which, in the presence of ONOO−, would lead to nitrotyrosine forma-
tion. Thismodiﬁcation is known to inactivateMnSOD [39,40]. Beneﬁcial
effects of the mitochondrially-targeted peptide have been observed
with disorders that have mitochondrial dysfunction in common,
such as neurodegenerative diseases, metabolic syndrome, muscle
atrophy and weakness, heart failure, and ischemia–reperfusion
injuries.
3.9. Manganese and its complexes with simple ligands
Evidence suggests that MnSalen, EUK-8 and MnBr8TM-3-PyP4+
transport Mn into the mitochondria of C. neoformans and into the
cytosol of Escherichia coli, respectively [29,82]. One of the hypotheses
is that mitochondria of eukaryotic cell have evolved from bacteria
[83]. Thus, the data related to the cytosol of prokaryotic E. coli are rel-
evant to the mitochondrial matrix of C. neoformans. In MnSOD-
knockout C. neoformans,MnSalen or the Mn released in mitochondria
from its complex has been shown to substitute for the lack of MnSOD
(see also underMnSalens section 66]). Lactobacillus plantarum accumu-
lates Mn to millimolar levels as a protection against oxidative stress[47]. Expressed permilligram of Mn, the SOD-like activity of Mn(II) lac-
tate is 65-fold lower than that of SOD enzymes [46]. Mn2+ protects E.
coliwhen growing aerobically at>0.5 mM[84], and exogenousMnmil-
limolar concentrations rescued O2−-sensitive phenotype of S. cerevisiae
lacking Cu,ZnSOD [46,50,85,86]. Finally, Mn2+ accelerates wild type
development, enhances stress resistance and rescues the life span of a
short-lived Caenorhabditis elegansmutant [87].
4. MitoQ10
The Liberman's, Skulachev's and Murphy's groups [49–51] clearly
established that both positive charge and lipophilicity play critical
roles in a molecule intended for mitochondrial targeting. Thus both
features were incorporated into the design of MitoQ10. The compound
was developed to enter cells driven by plasma membrane potential,
and mitochondria driven by mitochondrial membrane potential. In
MitoQ, a redox-cycling quinone, an analog of the ubiquinone of the mi-
tochondrial electron transport chain, was coupled to a cationic triphe-
nylphosphonium ion via long lipophilic alkyl chain [89]. The longer
the alkyl chain, the higher is the mitochondrial accumulation of MitoQ
[89]. An optimized MitoQ10 molecule, with a 10-carbon atom-alkyl
chain, has the capacity to suppress mitochondrial oxidative stress
(Fig. 3). In animals and cells, MitoQ10 is rapidly reduced two-
electronically by the mitochondrial respiratory chain to quinol,
MitoQH2, which is stable over a long-term incubation. The reduction
is essential for the compound to act as a reducing agent/antioxidant.
The major metabolite detected in vivo is monosulfonated MitoQ10,
which upon loss of sulfonate regenerates MitoQH2 [93].
The reactivity of MitoQ10 toward O2− and other oxygen radicals has
been studied in detail [94]. MitoQ10 reacts with O2− in water and meth-
anol with rate constants of 2.0×108 M−1 s−1 and 4.2×108 M−1 s−1,
respectively, forming semiquinone radical, MitoQH, which then dis-
mutes (disproportionates) to MitoQ10 and quinol, MitoQH2. Also,
MitoQH reacts with O2 in a reverse reaction with rate constants of
2.9×107 M−1 s−1 and 7.3x106 M–1 s–1 inwater andmethanol, respec-
tively (Fig. 4). The forward reaction is 10-fold more preferred over
the backward. The E1/2 for O2/O2− couple is −155 mV vs NHE and
−630 mV vs NHE in water and aprotic solvents, while it is −105 mV
vs NHE and −415 mV vs NHE for the MitoQ/ubisemiquinone in
water and UQ/UQH in aprotic solvents, respectively [94]. The reac-
tion of O2− with MitoQH2 is insigniﬁcant, with a rate constant of
≪105 M−1 s−1. MitoQH2 (but not MitoQ quinone), resides in the
hydrophobic core of membrane, where it can react with protonated
O2− (HO2) with a rate constant of ~106 M−1 s−1 (Fig. 4). Thus, catalysis
of O2− dismutation may be achieved via coupling of MitoQ10/MitoQH2
with other reactive species and components of the electron-transport
chain.
4.1. Reactivities of MitoQ10 toward other species
MitoQH2 rapidly reacts with ONOO− (whereby MitoQH is produced,
which then undergoes dismutation [89]) and is particularly effective
against lipid peroxidation [89]. Similar to other redox-able compounds,
MitoQ10 affects cellular transcriptional activity, presumably by mod-
ulating levels of cellular signaling species [53]. It blocks H2O2-induced
apoptosis and cell death, but the mechanism is not fully understood.
Further, a partially reduced form of MitoQH (semiquinone) can act as
a pro-oxidant. As is the case with Mn porphyrins (see below) and many
other redox-active compounds [44,95], MitoQ10 can act in vivo as a
pro-oxidant, which in turn could result in an adaptive response and
in upregulation of endogenous antioxidant defenses [89].
4.2. Mitochondrial accumulation of MitoQ10
MitoQ10 distributes predominantly into mitochondria [93]. In both
cytosol and mitochondria, MitoQ10 is bound and essentially no free
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Fig. 4. The mechanism of action of MitoQ with respect to scavenging O2−. These redox reactions are similar to those of ubiquinone in mitochondrial electron transport chain, and are
responsible for the production of low levels of superoxide. The rate constants listed refer to water. αTocH and αToc refer to α-tocopherol and α-tocopherol radical, respectively.
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likely bound at the matrix-facing surface of the inner membrane,
with the triphenylphosphonium cation in a potential energy well
close to the surface. The hydrophobic side chain is inserted into the
membrane [96].
4.3. MitoQ10 analogs
Due to the necessity to treat mitochondrial dysfunction, numerous
modiﬁcations of MitoQ10 based on the original design were subse-
quently reported. Instead of quinone, such derivatives bear vitamin
E (Mito-αToc), dihydroethidium (MitoSOX™ Red [97]), nitroxide
(Mito-Tempol, Mito-CP and Mito-CTP) [98,99], ebselen (a mimic of
glutathione peroxidase), MnSalen [99], NO donor (MitoSNO [100]),
and boronic acid peroxide sensor (MitoB [101]). MitoSOX™ Red,
where redox-able moiety is dihydroethidium (a stoichiometric scav-
enger of O2−), has been widely utilized as a mechanistic tool to prove
the involvement of mitochondrially produced superoxide in oxidative
stress [102]. Caution needs to be exercised as the effect of Mito moiety
on cellular bioenergetics was reported [103].
4.4. Therapeutic effects of MitoQ10
The compound has thus far been employed in numerous studies
and has already proven efﬁcacious in animal models of oxidative
stress, such as type I diabetes nephropathy, cold storage of renal
cells and kidneys, cardiac ischemia/reperfusion, endotoxin-induced
cardiac dysfunction, doxorubicin-induced cardiac toxicity, protec-
tion against increase in blood pressure in spontaneously hyperten-
sive rats, and prevention of amyloid β-induced impairments in
hippocampal synaptic plasticity in wild-type hippocampal slices
treated with exogenous amyloid β peptide. It has been also tested
in two phase-II clinical trials [104]. MitoQ10 was tested on its ability
to slow down Parkinson's disease progression, where no difference
was seen between placebo and MitoQ10 groups. The study provides
important safety data for long-term administration to humans. In a
chronic liver hepatitis study of HCV-infected patients, efﬁcacy in
decreasing serum alanine transaminase was observed, but no effect
on viral load was observed [104]. MitoQ10 has 10% oral availability.
Oral dosing to humans at 80 mg (1 mg/kg) results in maximal plasma
levels of 33.15 ng/mL at 1 h.
5. Mn porphyrins
5.1. Optimization of kcat(O2
−), bioavailability and toxicity
Mn porphyrins are among the most potent and true catalysts of
O2− dismutation, with kcat reaching the potency of SOD enzymes.
They have been designed to mimic the action of the enzyme catalytic
site. The detailed chemistry, biochemistry and biology of Mnporphyrins have been reviewed recently [44–46], and are brieﬂy
summarized below with most recent data included.
The reduction potential of the metal site of the enzyme, regardless
of the type ofmetal (Cu,Mn, Fe or Ni), is around themidway (~+300mV
vs NHE), between the potential for oxidation (−160 mV vs NHE) and
the reduction of superoxide (+890 mV vs NHE) (Fig. 5). Therefore,
both steps of the catalytic cycle are equally favored thermodynami-
cally; consequently, both oxidation and reduction of O2− by enzyme
occur with the identical rate constant of ~2×109 M−1 s−1 [105–107].
Further, dismutation is electrostatically facilitated, as the superoxide
anions are pulled toward the metal center through a tunnel encircled
with positively charged amino acids [108]. We attempted to derivatize
metalloporphyrins by mimicking the thermodynamics and electro-
statics of the enzyme catalysis. The unsubstituted porphyrins have
E1/2 for the MnIII/MnII redox couple ~−200 to −300 mV vs NHE
and cannot be reduced with O2− in the step one of the dismutation
process (Eq. (1)); the metal site reduction was a rate-limiting step
(Fig. 5) [82,109]. In order to make the metal site more reducible,
the electron-withdrawing groups were attached to the porphyrin
ring in meso and beta positions which resulted in a signiﬁcant
increase in Mn electron-deﬁciency which translated into a signiﬁ-
cant increase in E1/2. Across the wide range of compounds thus far
synthesized and commercially obtained, the E1/2 was increased by
up to ~800 mV relative to unsubstituted Mn porphyrins; the MnCl5-
TE-2-PyP4+ has the highest E1/2 of +560 mV vs NHE [46]. Based on
compounds explored, the structure-activity relationship (SAR) was
originally established [110], and later revised (Fig. 6). SAR shows that
as the E1/2 increases, the kcat increases as well. At E1/2 ~+200 mV, both
steps of the dismutation process occurwith similar rate constants [109].
As E1/2 becomes more positive and increases beyond +400 mV vs
NHE, the metal site becomes so electron-deﬁcient that it gets stabi-
lized in +2 oxidation state. Examples are Mn(II) complexes, MnBr8-
TM-3(and 4)-PyP4+ and MnCl5TE-2-PyP4+ (Table 1) [44–46]. These
compounds are not stable enough under physiological pH conditions
and readily lose metal. They are, however, excellent mechanistic tools,
proving that even a simple porphyrin ligand could be modiﬁed to
achieve the catalytic potency of a protein structure. Further increase
in E1/2 would stabilize Mn +2 oxidation state so much that the oxida-
tion of a metal complex would become unfavorable; i.e. the oxidation
of Mn porphyrin would become a rate-limiting step (Eq. (2)). Thus,
such complexes would be poor SOD mimics also. Based on SAR, the
ortho isomeric cationic Mn(III) N-alkylpyridylporphyrins were identiﬁed
as the most efﬁcacious SOD mimics thus far synthesized (Fig. 6).
Fig. 6 further clearly shows that at E1/2 ~+200 mV the cationic Mn
porphyrins are ≥100-fold more potent than compounds that have
no charge or possess anionic charges on their periphery [44–46].
Such data point to the crucial impact of electrostatics on the catalysis
of O2− dismutation by MnPs. In summary, the exploration of the
design of SODmimics shows that ortho isomeric compounds possess
a key property that is essential for their ability to catalyze O2−
MnTM-4-PyP5+
-1.0-0.8-0.6-0.4-0.20.00.20.40.60.81.0
Reduction Potential, V vs NHE
SOD
SOD mimics
O2- + e- + 2H+           H2O2 O2 +  e
-
              O2-
MnTnHex-2-PyP5+
MnTE-2-PyP5+
MnTBAP3-
MnT-2-PyP+ and most neutral 
Mn porphyrins, such as 
common MnTPP+ derivatives 
(not SOD mimics)
log kcat = 6.58
log kcat = 7.79
log kcat = 7.48 log kcat ~ 3.16(not an SOD mimic)
(E0 = -0.16 V)(E0 = +0.89 V)
log kcat ~ 9
(E1/2 ~ +0.30 V)
Fig. 5. The design of SODmimics was based on the same thermodynamics and electrostatics which play critical roles in enzyme catalysis. Potent SODmimics are those that have E1/2
for MIII/MII redox couple in the vicinity of the E1/2 of SOD enzymes, ~+300 mV vs NHE. All SOD enzymes regardless of the metal site, whether Mn, Fe, Cu or Ni, redox cycle at same
potentials [107,111]. Modiﬁed from ref [45].
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to the Mn site which (1) make the Mn(III) site electron-deﬁcient
and thus eager to accept electrons from the superoxide in the ﬁrst
step of the dismutation process; and (2) attract anionic superoxide
toward the singly charged Mn site.
The timeline for the optimization of SOD mimics is depicted in
Fig. 7. In Phase I we aimed at designing compounds whose kcat(O2−)
approaches that of an enzyme. As our research progressed, it became
clear that the efﬁcacy in vivo would also depend on the lipophilicity
of the compound, as well as on its bulkiness, size, and shape
(Fig. 7). The latter properties may hinder the cationic charges and
thus suppress the unfavorable approach of the compound to the
targeted biological molecules and thus decrease MnP toxicity. For
example, the interaction of cationic charges of the more planar para
isomer, MnTM-4-PyP5+ with nucleic acids, precludes the approach
of O2− to the Mn site, and in turn leads to the complete loss of its
SOD-like activity in vivo. Further, with cationic MnPs, a blood pres-
sure drop, as a side effect, was found in animal studies [44–46]. The
effect is lower with MnTnHex-2-PyP5+ than with MnTE-2-PyP5+,Fig. 6. Structure–activity relationship between the metal centered reduction potential, E1
kcat(O2−). At around +200 mV vs NHE, the kcat is ≥2 higher for cationic than for neutral and
of O2− dismutation. Modiﬁed from ref [82].presumably due to the larger hindrance of cationic charges by longer
alkyl chains [112,113]. Yet, in certain cases the hindrance of charges
may be unfavorable. For example, the cationic charges may favor the
approach of Mn porphyrin to the deprotonated anionic cysteine
residues of signaling proteins such as p50 and p65 subunits of NF-κB,
and thus facilitate the cysteine oxidation or glutathionylation, re-
spectively, which in turn would prevent NF-κB DNA binding and
suppress excessive inﬂammation [27,114,115].
The ﬁrst potent porphyrin-based SOD mimics, MnTM-2-PyP5+
and MnTE-2-PyP5+ (Fig. 1), were developed 15 years ago. Based on
the same principles, di-ortho imidazolium analog, MnTDE-2-ImP5+,
was subsequently synthesized. Because these compounds are fairly
hydrophilic and bear total pentacationic charge, it seemed at ﬁrst
unlikely that they would cross the blood brain barrier (BBB) and target
mitochondria. In an effort to facilitate transport across the BBB and
enhance accumulation within mitochondria, we have optimized the
properties of the cationic porphyrin by lengthening the alkyl chains of
meso pyridyl groups. While maintaining the total cationic charge,
and therefore the redox activity, we synthesized lipophilic Mn/2 for MnIII/MnIIP redox couple for cationic, neutral and anionic Mn porphyrins, and
anionic Mn porphyrins, indicating a vast contribution of electrostatics in the catalysis
Fig. 7. The timeline for the optimization of theMn porphyrin-based cellular redoxmodulators. Phase I studies were directed primarily toward generating compoundswith high kcat(O2−),
and were successfully accomplished. Pentacationic MnTE-2-PyP5+ has been identiﬁed as our lead compound. As the research progressed, the clinical relevance of such an excessively
charged drugwas questioned. To address this issue, analytical tools were developed to assess the pharmacokinetics of MnPs and their subcellular distribution. The ﬁrst data indicate that
even the fairly hydrophilic MnTE-2-PyP5+ targets mitochondria and crosses the BBB. In Phase II the MnP structure was modiﬁed to enhance its bioavailability, primarily lipophilicity, in
order to increase its transport across the BBB and mitochondrial accumulation. Lipophilicity was enhanced 10-fold: (1) by moving ethyl groups from ortho tometa positions; and (2) by
lengthening the alkyl chains by each additional carbon atom. Presently, Phase III efforts are directed toward reducing toxicity of MnPs, while maintaining high redox activity and lipo-
philicity. Longer-alkyl chain analogs possess surfactant-based toxicity. Such toxicity was suppressed by disrupting the hydrophobicity of alkyl chains via introduction of oxygen atoms:
(1) at the alkyl chain periphery, and (2) closer to the pyridyl nitrogens. In the ﬁrst case, with MnTMOHex-2-PyP5+ an unfavorable drop in hydrophobicity was observed relative to
MnTnHex-2-PyP5+ [109,117], while in the second case, with MnTnBuOE-2-PyP5+, not only was a high lipopohilicity preserved, but also a slight gain in catalytic potency was achieved
when compared to MnTnHex-2-PyP5+ [118].
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and MnTnOct-2-PyP5+. We subsequently showed that: (1) a number
of carbon atoms in alkyl chains are proportional to MnP lipophilicity
(the increase in alkyl chain length for one carbon atom increases
MnP lipophilicity ~10-fold) (Table 1) [91]; and (2) lipophilic mem-
bers accumulate more in E. coli and exert their efﬁcacy at signiﬁcant-
ly lower doses than hydrophilic analogs do [91,116]. MnTnHex-2-
PyP5+ and MnTnOct-2-PyP5+ are ~10,000- and 300,000-fold more
lipophilic than MnTE-2-PyP5+ [44–46]. Such a remarkable gain in
lipophilicity translates into a more than 3-orders of magnitude
increased in vivo efﬁcacy of lipophilic Mn porphyrins. Their thera-
peutic superiority is detailed below under “The in vitro and in vivo
efﬁcacy of Mn porphyrins.”
We have originally limited ourselves to the study of ortho isomeric
Mn(III) N-alkylpyridylporphyrins as they have the highest kcat(O2−)
among MnPs studied. Yet, our growing insight into the magnitude
of the effect of lipophilicity upon in vivo efﬁcacy tempted us to re-
visit the 10-fold more lipophilic meta isomers. A nice set of dataobtained in an E. coli study shows that higher bioavalibility of a MnP
can markedly compensate for its inferior redox potency. The meta
isomer MnTE-3-PyP5+ has a 10-fold lower SOD potency, but is 10-fold
more lipophilic than ortho MnTE-2-PyP5+. In turn, MnTE-3-PyP5+
accumulates at 10-fold higher levels within E. coli cell than MnTE-
2-PyP5+. Consequently, both compounds are equally able to protect
SOD-deﬁcient E. coli strain when growing aerobically [91].
The toxicity of cationic Mn(III) alkylpyridylporphyrins is at least
in part due to their micellar character, which arises from their
polar cationic nitrogens and hydrophobic alkyl chains (Fig. 7). Our
most recent efforts have been directed toward reducing the toxicity
of the lipophilic longer alkyl-chain analogs. Two strategies were
applied. Firstly, oxygen was introduced at the end of each alkyl
chain [109,117]; however this strategy signiﬁcantly reduced MnP
lipophilicity. The second approach was to bury oxygen atoms deep
into each of the alkyl chains, thus closer to the pyridyl nitrogens
[118]; such strategy preserved the lipophilicity and the SOD-like
potency of MnP, while largely diminished its toxicity.
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The excessive pentacationic charge of MnTE-2-PyP5+ set initial
doubts on its ability to enter mitochondria and cross the BBB. However,
it was shown by Liberman's, Skulachev's and Murphy's groups that cat-
ionic charge has a critical role in driving drug mitochondrial localization
[51]. The St. Clair's group recently showed that cationic MnTE-2-PyP5+
reduces incidence andmultiplicity of papillomas in amouse skin carcino-
genesis model in a manner similar to MnSOD enzyme (see details under
Skin carcinogenesis section) [119]. The data therefore suggest that the
MnP ends up inmitochondria andmore speciﬁcally in themitochondrial
matrix. Concurrently, Ferrer-Sueta et al. showed that ≥3 μM MnTE-2-
PyP5+ protects submitochondrial particles against oxidative stress im-
posed by peroxynitrite [120]. Subsequently, we quantiﬁed the accumu-
lation of MnTE-2-PyP5+ in mouse heart mitochondria: at 5.1 μM, its
levels are high enough to protect mitochondria against oxidative dam-
age [121].
6.1. Mouse heart studies
To test the hypothesis that lipophilicity has a critical impact on the
mitochondrial targeting of Mn porphyrins, we performed a mouse
study onMnTnHex-2-PyP5+. The data are discussed in relation to themi-
tochondrial accumulation of ~10,000-fold less lipophilic MnTE-2-PyP5+
(Fig. 2, Table 1) [121]. MnTnHex-2-PyP5+ was given ip at a maximal tol-
erable single dose of 2 mg/kg, while MnTE-2-PyP5+ was given ip at
10 mg/kg. The in vivo levels of MnPs were determined as previously de-
scribed, employing the LC/ESI-MS/MS method [45,122]. MnTE-2-PyP5+
was found in mouse heart mitochondria at (2.95±1.24) ng/mg protein
[121], and MnTnHex-2-PyP5+ was found at (12.17±8.48) ng/mg pro-
tein. Given the average value of mitochondrial volume of 0.6 μL/mg pro-
tein [123–130], the concentration ofMnTE-2-PyP5+ inmitochondriawas
5.1 μM,while it was 21.0 μM in the case ofMnTnHex-2-PyP5+. Assuming
a linearity in a drug accumulation upon dose increase, the data are nor-
malized to amg of drug injected and show thatMnTnHex-2-PyP5+ accu-
mulates ~20-fold more in mitochondria than does MnTE-2-PyP5+
(Fig. 8B). When cytosolic and mitochondrial fractions are compared,
MnTnHex-2-PyP5+ [121] accumulates ~5-fold more in mitochondria
than in cytosol (Fig. 8). The study supports the key impact of lipophilicity
on the transport of MnP into cells and its accumulation in mitochondria.
6.2. S. cerevisiae studies
Themouse cardiac data parallel the data generatedwith S. cerevisiae.
The accumulation of MnPs within mitochondria is proportional toFig. 8. (A) Accumulation of MnTnHex-2-PyP5+ in C57BL/6 mouse heart cytosol and mitocho
method [121]. (B) Comparison of the accumulation of hydrophilic MnTE-2-PyP5+ and lipop
jection. (C) The accumulation of MnTE-2-PyP5+ and MnTnHex-2-PyP5+ in wild type AB1157
the presence of 5 μMMn porphyrins in M9CAmedium [91]. One of the present evolutionary
coli envelope and cytosol, respectively [83]. Thus, the biodistribution within E. coli resemble
the raw data, obtained with 10 mg/kg single ip injection of MnTE-2-PyP5+ and 2 mg/kg sin
lation in tissues and subcellular fragments upon dose increase.the compound lipophilicity, which in turn is proportional to the
length of porphyrin alkyl chains [122,131]. The compound bearing
methyl (M) chains, MnTM-2-PyP5+ distributes evenly between yeast
mitochondria and cytosol, MnTE-2-PyP5+ resides ~2-3-fold more in
mitochondria than in cytosol, while the MnTnHex-2-PyP5+ is ≥90% in
mitochondria [122,131].
6.3. E. coli studies
One of the hypotheses is that eukaryotic cell mitochondria are evo-
lutionarily derived from bacteria [83]. Thus the E. coli membranes/
wall (envelope) and cytosol may be viewed as analogous to the
mouse mitochondrial membranes and matrix, respectively. Not sur-
prisingly, therefore, the mouse mitochondrial data are in excellent
agreement with the accumulation of cationic Mn porphyrins in E.
coli [91] (Fig. 8C). The accumulation was followed in both SOD-
deﬁcient and wild strains of E. coli. The accumulation was higher in
the SOD-deﬁcient strain, where MnPs exerted a remarkable ability
to substitute for the lack of cytosolic MnSOD and FeSOD [45,91]. In
agreement with the mouse heart studies, the lipophilic member of
the porphyrin series, MnTnHex-2-PyP5+, resides at ~30-fold more
in envelope and 100-fold more in the cytosol of E. coli than MnTE-
2-PyP5+ (Fig. 8C). E. coli data further show that all MnPs tend to
distribute more in envelope than in the cytosol (Fig. 8C). While
MnTnHex-2-PyP5+ accumulates ~twice more in envelope than in cy-
tosol, MnTE-2-PyP5+ distributes ~10-fold more in envelope than in
cytosol. The E. coli data also suggest that in addition to the mito-
chondrial matrix, MnTnHex-2-PyP5+ could reside within mouse cardi-
acmitochondrial membranes, and/or be placed at the innermembrane/
matrix interface, where the lipophilic chains may be stuck within the
membrane while cationic heads reach the matrix (similar to MitoQ10).
It can thus mimic both isoforms of mitochondrial enzymes: MnSOD
and Cu,ZnSOD. Further studies are needed to address the compart-
mentalization of MnTnHex-2-PyP5+ within mitochondria.
7. Accumulation of Mn porphyrins in brain
The critical effect of lipophilicity of MnPs upon their in vivo action
is further evidenced in those animal studies where transport across
BBB is required for their efﬁcacy (stroke, subarachnoid hemorrhage,
pain, cerebral palsy, neurologic disorders, etc) [42–44]. The hydro-
philic MnTE-2-PyP5+ accumulates in brain over a 7-day period after
a single 10 mg/kg ip injection [121]. As expected, MnTnHex-2-PyP5+
accumulates in brain at ~9-fold higher levels [112], which agrees with
its 20-fold higher mitochondrial accumulation (Figs. 8 and 9). MnTE-ndria at 6 h after single ip injection of 2 mg/kg. Data obtained using the LC/ESI-MS/MS
hilic MnTnHex-2-PyP5+ in C57BL/6 mouse heart mitochondria at 6 h after single ip in-
E. colimembranes/cell wall (envelope) and cytosol after E. coliwas incubated for 1 h in
hypotheses is that eukaryotic mitochondrial membranes and matrix are derived from E.
s the biodistribution within heart mitochondria. It must be noted that recalculation of
gle ip injection of MnTnHex-2-PyP5+, were done assuming a linearity in drug accumu-
Fig. 9. The distribution of MnTE-2-PyP5+ and MnTnHex-2-PyP5+ in murine brain at 24 h
after single ip injection [112]. Brain levels of lipophilic MnTnHex-2-PyP5+ are 9-fold
higher than of hydrophilic MnTE-2-PyP5+. MnTE-2-PyP5+ and MnTnHex-2-PyP5+ were
injected ip at 10 mg/kg and 2 mg/kg, respectively. Data are expressed per mg of drug
injected assuming a linearity in drug brain accumulation upon dose increase.
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2 mg/kg, respectively. Their mitochondrial and brain levels were recal-
culated per mg of drug injected, assuming a linearity in drug accumula-
tion upon dose increase. Such agreement is due to the fact that in both
cases the ability of MnP to cross lipid membranes plays a major role.
8. Accumulation of Mn porphyrins in tumor tissue
The ﬁrst set of data on MnP accumulation in tumors was obtained
in a 4T1 mouse breast cancer model where MnTnHex-2-PyP5+ was
administered during the duration of experiment twice daily ip at
1.6 mg/kg with and without sodium ascorbate [132]. The Mn porphy-
rin accumulated ~5-fold more in tumor (sc xenografts were estab-
lished on right ﬂank) than in the muscle taken from the left leg
[132]. The enhanced accumulation in tumor relative to muscle was
observed when mice were treated either with MnP alone or with
MnP/ascorbate. Combined administration with ascorbate is relevant
due to the high levels of ascorbate in vivo, where MnP action is likelyFig. 10. The reactivity of Mn porphyrins toward reactive species (A) and transcription factors
oxygen and nitrogen species, such as O2−, ONOO−, ClO−, NO2, CO3−, would produce antioxida
removed by abundant peroxide-removing systems. The ONOO− reacts with MnTE-2-PyP5+ wh
tainsMn in+2 oxidation states (k≫107 M−1 s−1 at 37 °C) [135,136]. MnTE-2-PyP5+ reacts a
rapidly with ClO− with a rate constant of k≫106 M−1 s−1 [Ferrer-Sueta et al., unpublished].
MnPs that are potent SOD mimics would likely favor reaction with NO2 too.coupled to ascorbate redox cycling. Other reductants, such as gluta-
thione, tetrahydrobiopterin and protein cysteine residues, may be
also involved in MnP reduction (from MnIIIP to MnIIP) and its
redox-cycling [44,114,115,133]. Once reduced, MnP loses a single
charge from the Mn site and in turn becomes more hydrophobic
[132]. The gain in lipophilicity is related to the length of porphyrin
alkyl chains in a bell-shape fashion: ≥10-fold increase was found
with MnTE-2-PyP5+ and MnTnHex-2-PyP5+ [132]. Such increased
lipophilicity may enhance MnP subcellular accumulation. Most recent
data on MRI imaging of prostate cancer, employing Mn porphyrins as
contrast agents, show also that MnTE-2-PyP5+ distributes more in
prostate tumor than in the surrounding tissue [134].
9. Mechanism of action of Mn porphyrins
Alike MnSOD enzyme, the Mn porphyrins affect levels of reactive
species and activation of transcription factors, whereby acting as
ﬁne cellular redox modulators. These actions may be independent
or related, as reactive species are both strong oxidants and also major
signaling species. The MnP-based SOD mimics have been proven
efﬁcacious in numerous in vitro and in vivo models, and the efﬁcacy
was reproduced in various laboratories both within and outside the
United States [13,27,44–46,132].
9.1. Reactivity toward reactive species
Increased knowledge about the chemistry and biology of redox-
active compounds and the role of reactive species and endogenous
antioxidants makes it clear that synthetic SOD mimics as well as stoi-
chiometric scavengers of superoxide are not speciﬁc towards O2−
(Fig. 10). The possible reactions of Mn(III) N-alkylpyridylporphyrins
are depicted in Fig. 10 to point to the complexity of in vivo systems
and to emphasize the need to further the knowledge on the biology
of MnPs and cellular components and their mutual interactions.
The diverse reactivities of MnPs make mechanistic studies more(B). The reactivity of Mn(III) substituted pyridyl(or imidazolyl)porphyrins toward several
tive effects [44–46]. Under physiological conditions, H2O2 formed during dismutation is
ich has Mn in +3 (kred=3.4×107 M−1 s−1 at 37 °C), and with MnTE-2-PyP4+ that con-
lso with NO (k ~106 M−1 s−1) [137]. Based on the preliminary data, MnTE-2-PyP5+ reacts
Based on the thermodynamic and kinetic data thus far published on ortho isomers, those
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out the predominant species involved.
While mechanistic aspects need further exploration, the beneﬁcial
therapeutic effects are obvious because the failure to remove O2− by
MnP would result in increased levels of its progeny, such as, OH,
ONOO−, NO2, CO3−, and lipid peroxyl radicals. Thus, the potent
MnP-based SODmimics would efﬁciently suppress not only the levels
of O2− but of all species originated from it.
The electron-deﬁcient metal porphyrin center favors binding of the
anionic ONOO− to Mn(III) or Mn(II) (reduced by cellular reductant or
O2−), which is followed by the one-electron or two-electron reductions
of ONOO− to NO2 or NO2−, respectively [135,136]. Reduction of CO3−
by MnPs and reactivity toward NO have also been reported (Fig. 10A).
Further, preliminary data [Ferrer-Sueta et al., unpublished] indicate
that MnPs have high ability to reduce ClO−. Reduced Mn(II) porphy-
rins have fairly high reactivity towards molecular oxygen as
well (Fig. 11). Among the rate constants thus far determined, the
highest are those related to the elimination of O2− and CO3−, followed
by kred(ONOO−) [44–46,136]. The type of reaction favored in vivo
will ultimately depend upon the levels of MnPs, reactive species,
cellular reductants and their co-localization with MnPs.9.2. Mn porphyrins and cellular reductants
Electron deﬁciency of a Mn site facilitates easy reduction of Mn
porphyrins not only with O2− but with cellular reductants, such as
ascorbate, glutathione, tetrahydrobiopterin and ﬂavoproteins of
mitochondrial respiration. As those reductants are highly abundant
in vivo, the removal of O2− by MnPs would likely be coupled with
redox cycling of ascorbate or glutathione [133,138,139]. Thus, in a
ﬁrst step, ascorbate would reduce MnIIIP to MnIIP. Subsequently, the
MnIIP would reduce O2− to H2O2. Consequently, MnPs may in vivo
act as superoxide reductases rather than superoxide dismutases [140].
MnPs could in vivo increase levels of H2O2 either via catalysis of
O2− dismutation or reaction of MnIIP with O2, or via catalysis of ascor-
bate oxidation (Fig. 11), but only if the cellular levels of peroxide-
removing enzymes are reduced and therefore the physiological redox
status perturbed. The scenario where MnP may drive H2O2 production
from electron transport chain, as discussed for MnSOD enzyme by
Buettner et al. [16] (see Introduction), might be operative as well.
We and others have shown in different cancer cell lines that, in
the presence of exogenous ascorbate, MnPs catalyze ascorbate oxi-
dation, and in turn increase levels of H2O2 above the endogenousFig. 11. The generation of the reactive oxygen species by Mn porphyrins coupled to ascorb
erate antioxidative effects. Yet, if peroxide-removing enzymes are reduced, the H2O2 levels
dative stress. Under such conditions, the ability of MnPs to catalyze ascorbate oxidation w
redox cycles between Mn +3 and +2 oxidation states while transferring electron to ascor
with O2 or O2−, and in either case H2O2 would be eventually produced. The same is valid f
the reaction of A− with O2 [153–159]. The type of outcome, antioxidant or pro-oxidative, w
SODs and peroxide-removing enzymes, levels of reactive species that MnP would encountecapacity of cells to remove it. Consequently, the cell killing was
observed [95,141,142]. Similar effects were seen in E. coli study.
The protectiveness of Mn porphyrins towards SOD-deﬁcient E. coli
was fully reversed in the presence of exogenous ascorbate, due to the
increased production of H2O2. However, E. coli initially ceased to grow,
but recovered over time by upregulating endogenous peroxidases and
catalases [95]. Such an outcome suggests that in those studies where
the anticancer effect of MnP was reported [143], the MnP might have
acted in partnership with ascorbate by provoking the cellular adaptive
response. Dorai et al. data [144] suggest an adaptive response to the ac-
tion of MnTnHex-2-PyP5+ in a rat warm renal ischemiamodel also (see
below under Renal ischemia–reperfusion section). This action is simi-
lar to the upregulation of endogenous antioxidants when the oxida-
tive stress was imposed by physical exercise [145]. A response to
enhanced expression of MnSOD and concomitant increase in oxida-
tive stress, by upregulation of some of the peroxide-removing en-
zymes, was observed by Kim et al. [146].9.3. Reactivity of MnPs toward transcription factors
Several in vitro and in vivo animal studies show that via remov-
ing signaling reactive species MnP inhibits the activation of HIF-1α,
AP-1 and that Sp1 with concomitant suppression of oxidative stress
[119,143,147–149]. In such cases the antioxidative action of MnP
exerts antioxidative effects (Fig. 10B). The identical ability to accept
and donate electrons (as exempliﬁed by identical rates to reduce
and oxidize O2− [109]) indicates that MnTE-2-PyP5+ acts as an equally
able pro-oxidant and antioxidant in the dismutation process. Thus, it
readily oxidizes ascorbate [142] and cysteine of glutathione in an
aqueous system [27]. Further, the data on NF-κB DNA binding in
cellular and animal models [150,151] suggest that cationic Mn por-
phyrin can approach the deprotonated, anionic cysteines of p50 of
NF-κB in nucleus and subsequently oxidize them, which would lead
to the suppression of NF-κB activation [151,152]. In this case, the
pro-oxidative action of MnPs translates into antioxidative effects. It
is possible that cysteine oxidation by MnP may happen with other
transcription factors as well. However, in studies of malignant
lymphoma cells that were treated with glucocorticoids, an oxidative
cytosolic event, such as p65 glutationylation by MnP in the presence
of H2O2, resulted in glutathione deprivation, enhanced oxidative
stress and in turn enhanced cancer cell killing [114,115]. Cases such as
these indicate the need to distinguish between themechanismof action
of Mn porphyrins and the nature of the observed effects.ate redox cycling. With abundant peroxide-removing systems, such action would gen-
may increase and activate cellular transcription, which would in turn perpetuate oxi-
ould contribute to the progression of oxidative stress. The metal site of Mn porphyrin
bate and producing ascorbyl radical, A−. The reoxidation of MnIIP to MnIIIP may occur
or the self-dismutation of A− and O2−, the reaction of A−, HA− and A2− with O2−, and
ould depend upon the cellular redox status, the levels of cellular endogenous defenses,
r, levels of MnP and their site of accumulation. Modiﬁed from ref [142].
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MnTM-2-PyP5+ ameliorates diabetes-induced oxidative stress and
affects life-span of diabetic rats when administered for 2 months subcu-
taneously at 1 mg/kgﬁve times/week followed by aweek of rest, starting
at the onset of diabetes [160]. MnTM-2-PyP5+ treatment suppressed
lipid peroxidation and nitrotyrosine formation, prevented aconitase inac-
tivation, and reversed the induction of Na+/H+ exchangers [147]. How-
ever, when the administration started 1 week after the onset of diabetes,
no protection against oxidative stress and diabetic complications was
detected [161]. Moreover, MnTM-2-PyP5+ contributed to the kidney
damage: increased urinary protein, lysozyme and blood urea nitrogen
levelswere found. Further, its administration increasedmalondialdehyde
levels and decreased activity of glucose-6-phosphate dehydrogenase.
This enzyme has a unique role, as it is a principal source of cellular reduc-
ing equivalents in the formof NADPH,which supports glutathione regen-
eration. In stroke studies, MnTE-2-PyP5+was only efﬁcacious if given not
later than 6 h after middle cerebral artery occlusion (MCAO) [162]. Dif-
ferences in the effects produced with different dosing regimen are
likely related to the changes in the cellular balance between the reac-
tive species and endogenous antioxidants as the disease progresses.
Tan et al. recently showed a remarkable ability of MnTnHex-2-PyP5+
to reduce the severity of motor deﬁcit in a cerebral palsy model, but
only when given to rabbit dam prior to uterine ischemia/reperfusion.
The effect was lost if MnP was given during reperfusion, which is due
to its slow accumulation in fetal brain (see below under Cerebral
palsy section) [163].
9.5. Mn porphyrins and tumors
Numerous reports provide evidence that tumors are more oxida-
tively stressed than normal tissue [164–177]; moreover, tumors
adapt so that they utilize oxidative stress as a “signaling” tool for
their own progression. Yet, tumors are also vulnerable to any addi-
tional increase in oxidative stress, which may eventually lead to cell
apoptosis, exempliﬁed by a narrower bell-shape curve in Fig. 12.
Data have been provided which show that MnP can suppress tumor
progression by either: (1) removal of reactive species as witnessed
by the suppression of oxidative stress (see below); or (2) increased
production of reactive species (Fig. 12). The type of MnP action de-
pends on cellular redox status, timing of MnP administration, levelsFig. 12. A tumor is frequently under oxidative stress, a “physiological” status that is vi-
sualized here by the maximum of its bell shape curve shifted for Δ1 towards higher RS
levels. The increased level of RS is a signal for the upregulation of the genes needed to
support tumor angiogenesis and progression [184,185]. However, a tumor is vulnera-
ble, and any further increase (Δ2) in oxidative burden would force tumor cells to un-
dergo death. Larger oxidative disbalance (Δ3) needed for normal cells to undergo
death is being currently exploited to selectively destroy tumor. The strategy to treat tu-
mors may be either to remove RS or to vastly increase their levels [27,95]. The latter
strategy has already been used in clinic; one example is the combination of ascorbate
and the redox cycling agent menadione which results in increased peroxide levels
[186–190]. Parthenolide also has such a pro-oxidative effect, which is exerted by the
selective upregulation of NADPH oxidases [183]. HIF-1α inhibition, and subsequent
suppression of angiogenesis, is a part of the ﬁrst strategy where MnP scavenges RS,
and thereby affects cell signaling [143,149].of reactive species and MnPs and their co-localization, levels of en-
dogenous antioxidants, and MnP cellular and subcellular distribution.
4T1 breast cancer cellular and mouse studies provide evidence
that removal of reactive species by MnTE-2-PyP5+ prevents HIF-1α
activation and VEGF expression, and thus tumor angiogenesis. Con-
comitant decrease in oxidative stress was detected [143,148,149].
Similarly, in a skin carcinogenesis mouse model, MnP suppressed
AP-1 activation and protein oxidative modiﬁcation [178]. When dif-
ferent cancer cell lines were cultured in the presence of MnP and an
excess of ascorbate, the effects observed were pro-oxidative; a similar
trend was seen in a 4T1 mouse model [142]. These effects are likely
due to the inability of endogenous enzymes to manage excessive
H2O2 produced by MnP-catalyzed ascorbate oxidation (Fig. 11) [142].
Anticancer drugs which function by increasing tumor oxidative
burden have been widely used. Prostate cancer cells often exert in-
creased generation of reactive oxygen species from mitochondria [179]
or NADPH oxidases [180], which is in part due to the decreased
levels of antioxidant enzymes, such as MnSOD, Cu,ZnSOD, and cata-
lase [181,182]. Partenolide selectively activates NADPH oxidases,
mediating oxidative stress in prostate cancer cells by both increas-
ing ROS generation and decreasing antioxidant defense capacity,
which results in radiosensitizing effects. Yet, the oxidative stress in
normal prostate epithelial cells was reduced [183].
9.6. The in vivo and in vitro efﬁcacy data
Below are summarized data that showmore than1000-fold increase
in the in vivo efﬁcacy of lipophilic relative to hydrophilicMnPs,which at
least in part reﬂects their ability to enter the cell and its critical compart-
ments and cross the BBB. Also, a few studies are cited whose data
strongly suggest that MnPs can indeed mimic mitochondrial MnSOD.
MnTnHex-2-PyP5+ has been studied in several models of central
nervous system injuries and has been found efﬁcacious at very low
single or multiple doses ranging from 0.05 to 3.2 mg/kg/day in animal
models and from 0.1 to 1 μM in E. coli studies. The hydrophilic MnTE-
2-PyP5+ was up to 120-fold less efﬁcacious at 6 to 15 mg/kg single or
multiple doses (ip, iv, sc, icv) in animal models, and from ~20 to
50 μM in cellular models [44,46]. MnTnHex-2-PyP5+ was remarkably
efﬁcacious in stroke and hemorrhage rodent models [112,150], rabbit
cerebral palsy [163,191], brain glioma study [192], organotypic hyp-
pocampal slice model of oxygen glucose deprivation [190], rat eye
hypertension [193], rat lung radiation [194], rat renal ischemia reper-
fusion model [144,195], E. coli model [116], and ataxia telangiectasia
radiation cellular model [196]. The most remarkable efﬁcacy of
MnTnHex-2-PyP5+ was found in the rabbit cerebral palsy model (see
below under Cerebral palsy section). Ataxia telangiectasia (AT) is a
rare neurodegenerative disease in which the impaired mitochondrial
function of lymphoblastoids causes AT patients to be particularly sensi-
tive to radiation. In a cellular model, the 1 μM MnTnHex-2-PyP5+ was
the most efﬁcacious among a wide range of compounds studied, fol-
lowed by 56 μMMnTMx-2-PyPy+. MnTMx-2-PyPy+ describes a prepa-
ration that was incompletely quaternized (methylated) MnT-2-PyP+.
It contains Mn porphyrins bearing different number of methyl groups
from 0 to 4, and therefore total charge from 1+ to 5+. The prepara-
tion was thus more lipophilic relative to a single compound, MnTM-
2-PyP5+, bearing 4 methyl groups and a pentacationic charge. MnCl2
was marginally protective, but it was used at only 1 μM concentra-
tion. Other compounds studied are: MnSalen derivatives (EUK-8,
EUK-134 and EUK-189), Mn cyclic polyamines (M40403, M40304),
MnTE-2-PyP5+, PEG-ylated porphyrin, MnTTEG-2-PyP5+, and MnBr8-
TSPP3− [196]. The study suggests that positive charge of a compound
and its lipophilicity are key features that allow MnTnHex-2-PyP5+ to
radioprotect mitochondria. In an organotypic hyppocampal slice model
of oxygen/glucose deprivation [190], we explored the most lipophilic
member of the alkylpyridyl series: the octyl compound, MnTnOct-2-
PyP5+. The compound was >1000-fold more efﬁcacious than
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2-ImP5+. In a brain tumor study, MnTnHex-2-PyP5+ was an efﬁcacious
radio- and chemo-sensitizer. Its efﬁcacy is at least in part due to its abil-
ity to cross BBB and accumulate in brain mitochondria [44].
However, lipophilic MnTnHex-2-PyP5+ also has micellar charac-
teristics, as it bears cationic polar heads and hydrophobic chains.
This contributes at least in part to its increased toxicity. Zn analog,
ZnTnHex-2-PyP5+, exerts no dark toxicity [197], which suggests
that redox activity of a metal site contributes to the toxicity of
MnTnHex-2-PyP5+. Our efforts were recently directed towards re-
ducing toxicity while maintaining high redox potency and high lipo-
philicity of MnTnHex-2-PyP5+. Its oxygen derivative, MnTnBuOE-2-
PyP5+, was synthesized (Fig. 7), and has enhanced kcat(O2−),
lipophilicity and greatly reduced toxicity (Fig. 7) [118].
9.7. Skin carcinogenesis
In a TPA-skin carcinogenesis model, MnTE-2-PyP5+ was adminis-
tered in a timelymanner, after cells underwent apoptosis and before pro-
liferation, and was applied to a mouse skin at 5 ng/day, 5 days per week,
for 14 weeks [178].Mnporphyrin decreased the incidence andmultiplic-
ity of papillomas from 31 (in control mice) to 5 (Fig. 13). In a similar
study with MnSOD-overexpressor mice, MnSOD suppressed both apo-
ptosis andproliferation, and theﬁnal outcomewas therefore diminished:
the number of papillomas decreased from19 to 9 (Fig. 13) [20,178]. Fur-
thermore, MnTE-2-PyP5+ suppressed oxidative stress as shown by the
reduced levels of carbonylated proteins. It greatly suppressed AP-1 acti-
vation and proliferation and consequently the incidence of cancer,
without affecting levels of the pro-apoptotic, tumor suppressor tran-
scription factor p53 (Fig. 13). The MnP antioxidative mode of actionFig. 13. MnTE-2-PyP5+ mimics MnSOD in suppressing skin carcinogenesis. The reduction in
vation (C), presumably via removing signaling species, which in turn suppresses oxidative
with 7,12-dimethylbenz (a)-anthracene (DMBA). TPA is a tumor promoter 12-O-tetradeca
apoptosis and proliferation (MnP/TPA), and after apoptosis and before proliferation (TPA/
and therefore the effect was much more pronounced than in the former case (A). With MnS
(B), which diminished the enzyme effect upon cancer incidence relative to the effect of timwas proposed as a means to remove signaling reactive species, and
thereby spare biological targets and prevent transcriptional activity.
9.8. UVB-mediated skin damage
Mitochondrial DNA, mtDNA, is organized as nucleoids in the mi-
tochondrial inner membrane. Nucleoids consist of mtDNA-protein
macromolecular complexes containing 2–8 mtDNA molecules as-
sociated with various proteins such as mitochondrial transcription
factor A, mitochondrial single-strand DNA binding protein and mi-
tochondrial DNA polymerase Polγ protein [198]. Polγ is the only
known polymerase enzyme responsible for the replication and repair
of mtDNA. mtDNA is more sensitive to UV-induced damage than is
nuclear DNA, as it lacks histones and an elaborate repair system.
Depilated mice in resting phase of hair cycle were irradiated with
5 kJ/m2 of UVB radiation. The oxidative damage of Polγ protein (its
nitration and subsequent inactivation [198–200]) was greatly
reduced in MnSOD+/+ wild type mice as compared to MnSOD knock-
out mice (Fig. 14A). The UVB radiation did not affect levels of Polγ.
Such data indicate that MnSOD is a mitochondrial ﬁdelity protein that
protects Polγ against UV-induced inactivation. The full protection of
Polγwas observed (either at 1 h or 24 h after UVB treatment) in skin ly-
sates of MnSOD+/− mice, treated twice daily ip for 2 days before UVB
with 5 mg/kg of MnTE-2-PyP5+ (Fig. 14) [198]. The data provide further
evidence that this MnP is indeed a MnSOD mimic.
9.9. Pain study — chronic morphine tolerance
Acute morphine has been shown to suppress pain in a mouse paw
exposed to heat. When given chronically over 4 days, the analgesicincidence and multiplicity of tumors (A and B) was achieved by inhibiting AP-1 acti-
stress as observed by reduction of protein carbonyl formation (D). Tumor was induced
noylphorbol-13-acetate. MnTE-2-PyP5+ (MnP) was injected in two ways, before both
MnP). In the latter case, MnP did not attenuate apoptosis, but reduced proliferation,
OD-overexpressor mice, MnSOD attenuated both apoptotic and proliferative pathways
ely administered MnSOD mimic. Modiﬁed from refs [20,178].
Fig. 14. The mouse model of UVB radiation-induced oxidative damage. MnSOD+/+ wild type and heterozygous MnSOD knockout mice, MnSOD+/−were studied. The UVB radiation
caused nitration and subsequent inactivation of Polγ, a polymerase enzyme responsible for the replication and repair of mtDNA. With MnSOD+/+ mice, the oxidative damage was
signiﬁcantly reduce, and was fully suppressed when mice were treated with 5 mg/kg of MnTE-2-PyP5+ ip twice daily for 2 days before radiation. Quantiﬁcation of Polγ co-
immunoprecipitation by anti-3-nitrotyrosine antibody in mice skin lysates in terms of arbitrary units, is shown. **Pb0.01, ***Pb0.001 compared with control; ###Pb0.001 com-
pared between 1 h and 24 h after UVB treatment, #Pb0.05 compared between 1 h and 24 h after UVB treatment; ^Pb0.05 compared between MnSOD+/+ and MnSOD+/− mice;
^^Pb0.01 compared between MnIIITE-2-PyP5+ and saline pre-treatment. Modiﬁed from ref [198].
Fig. 15. Themouse model of chronic morphine tolerance. Mn porphyrins were able to ei-
ther substitute for or protect MnSOD from inactivation in a mouse whole brain homoge-
nate when injected ip at 3 mg/kg (MnTE-2-PyP5+) and 0.1 mg/kg (MnTnHex-2-PyP5+)
for 4 days along with morphine. No effect was seen on the expression of MnSOD protein.
T describes tolerant group (which develops chronic morphine tolerance), and V is a vehi-
cle group. The 30-fold increased efﬁcacy of MnTnHex-2-PyP5+ resembles its 20-fold in-
creased mitochondrial accumulation relative to MnTE-2-PyP5+. The higher ability of
MnTnHex-2-PyP5+ to cross BBB further potentiates its effect in comparison with MnTE-
2-PyP5+. Modiﬁed from ref [201].
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with Mn porphyrins (Fig. 15) [44,201]. Chronic morphine tolerance
causes MnSOD inactivation but does not affect its expression levels
(Fig. 15). The oxidative modiﬁcations of neurotransmitters, such as glu-
tamate transferase and glutamine synthase, also contribute to the de-
velopment of chronic morphine tolerance [201,202]. Both MnTE-2-
PyP5+ and MnTnHex-2-PyP5+ were able to prevent MnSOD inactiva-
tion (Fig. 15) [201]. The activity of Cu,ZnSOD was affected by neither
chronic morphine tolerance nor by MnPs (Fig. 15). A lipophilic
MnTnHex-2-PyP5+ was ~30-fold more efﬁcacious, which agrees well
with its ability to accumulate ~20-fold more in mitochondria than
does MnTE-2-PyP5+. As inhibition of chronic morphine tolerance oc-
curs at the level of the central nervous system, the ability of a drug to
cross the BBB also plays a role. MnTnHex-2-PyP5+ is able to cross
the BBB ~9-fold more than MnTE-2-PyP5+ [112,122]. Oxidative
stress was suppressed, as seen by the reduction in formation of 8-
hydroxy-2′-deoxyguanosine [122].
9.10. Renal ischemia–reperfusion
Two sets of data on renal/ischemia have been reported. The ﬁrst
study by Saba et al. provided data on MnSOD inactivation which is
similar to the data obtained in a mouse pain model (Fig. 16) [195].
Rats were subjected to a right nephrectomy and renal artery occlu-
sion (40 min) followed by 18 h reperfusion. MnP was given as a single
0.05 mg/kg injection via iv route at 30 min and 24 h before ischemia/
reperfusion. The levels of MnSOD were not affected by ischemia/
reperfusion, yet MnTnHex-2-PyP5+ prevented enzyme inactivation
if given 24 h before the oxidative insult. Further, Mn porphyrin
signiﬁcantly suppressed the protein nitrotyrosine formation in a
renal tissue. ATP synthase-β subunit was identiﬁed as a key protein
induced by MnP and a complex V (ATP synthase) as a target of renal
ischemia/reperfusion.
The second study of rat warm renal ischemia by Dorai et al. was
conducted with 0.1 mg/kgMnTnHex-2-PyP5+. The MnPwas given in-
tramuscularly at 24 h before, during renal artery clamp and 24 h after
surgery, as a part of a cocktail containing Krebs cycle intermediates,
α-ketoglutarate and L-aspartate, and growth factors bFGF, BMP-7,
SDF-1 and EPO [144]. At 48 h, the kidneys were harvested and exam-
ined. Signiﬁcant reversal of morphological changes and a decrease in
the speciﬁc ischemic markers lipocalin-2, mucin-1 and galectin-3
were detected. Quantitative reverse transcriptase–polymerase chain
reaction in treated animals reveal multifold upregulation of several
antioxidant genes, including MnSOD, extracellular Cu,ZnSPOD, perox-
yredoxins and thioredoxin reductase.9.11. Cerebral palsy
The role of MnSOD and mitochondria in neurological disorders,
such as cerebral palsy and epilepsy, has been established [203,204].
Fig. 16. The rat renal ischemia/reperfusion model. MnTnHex-2-PyP5+ (MnP) preserved MnSOD activity but did not affect protein expression. It was given iv into penil vein, at
0.05 mg/kg 30 min and 24 h before ischemia/reperfusion. SH describes sham, and I/R ischemia/reperfusion. Modiﬁed from ref [195].
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premature infants is thought to be the result of hypoxic–ischemic
injury to the cerebral white matter; the main cell type injured is de-
veloping oligodendrocyte, Ol [204]. Overexpression of MnSOD in
developing Ols provides protection to mitochondrial membrane po-
tential and reduces cell death in a mild form of cysteine deprivation,
indicating glutathione as a primary defect of energy disruption [204].
In a rabbit dam uterus ischemia model, only lipophilic MnTnHex-2-
PyP5+, which crosses the BBB to a 9-fold higher level and accumulates
20-fold more in mitochondria than MnTE-2-PyP5+ was successful in
suppressing symptoms of cerebral palsy [163]. Both compounds were
given iv to rabbit dam 30 min before and 30 min after 40 minute-
long uterine ischemia. MnTnHex-2-PyP5+ was tested at 0.12 mg/kg
and 1.20 mg/kg, and MnTE-2-PyP5+ at 15 mg/kg. The lower dose of
MnTnHex-2-PyP5+wasmore efﬁcacious, while the higher dose carried
some toxicity. In a control group, 30 kits were stillborn, 38 were hypo-
tonic, and 28 healthy out of 96 fetuses at C-section; in MnTnHex-2-
PyP5+-treated groups, 11 kits were stillborn, 10 hypertonic, and 36
normal out of 51 fetuses (no still born kits were found with lower
dose of MnTnHex-2-PyP5+). However, when the MnTnHex-2-PyP5+
was given only during reperfusion, due to its insufﬁciently fast accumu-
lation in a fetal brain (as followed by MRI, the tmax ~2 h), the effects
were small: 20 kits were stillborn, 14 hypertonic, and 8 healthy out
of 41 fetuses [163].
10. Summary
We have described here in details two strategies to bring the redox-
activemolecule intomitochondria. Both strategieswere shown success-
ful in ameliorating mitochondrially-based oxidative stress disorders.
The 1st strategy explores the use of true SOD mimics which are able
to efﬁciently catalyze the dismutation of O2− and accumulate in mito-
chondria. Such compounds belong to the class of cationic Mn(III) N-
substituted pyridyl- and N,N′-disubstituted imidazolylporphyrins.
Some of them have rate constants, kcat(O2−), nearly identical in
magnitude to those of SOD enzymes. Liberman and Skulachev point-
ed to the preferred accumulation of monocationic phosphonium
compounds in mitochondria. Subsequently, Murphy et al. pointed
to the critical role that lipophilicity plays also. The cationic Mn
porphyrin molecule combines in its structure critical features that
allow it to mimic both the action and the site of mitochondrial en-
zyme, MnSOD: (1) redox active Mn site, (2) multiple cationic charge,and (3) four alkyl chains. The longer the alkyl chains, the higher the
Mn porphyrin accumulation in mitochondria. MnTE-2-PyP5+ bears
fairly short ethyl chains (Fig. 2), yet its multiple pentacationic charge
compensates for its inferior lipophilicity; in turn this molecule
reaches the mitochondria where it was shown to mimic MnSOD
action in several different models of oxidative stress. The 2nd strategy
has been the one employed in the design of MitoQ10, where redox-
active quinone was linked to monocationic triphenylphosphonium ion
and lipophilic alkyl chain in order to enter mitochondria. As a conse-
quence of such elegant design, numerous Mito-derivatized redox modu-
lators, able to reduce levels of a variety of reactive species (H2O2, NO,
ONOO−, lipid peroxyl and alkoxyl radicals, etc) which are involved in
mitochondrial dysfunction, have been reported: MitoSOX™ Red,
MitoSNO, MitoSalen, Mito-Nitroxides (Mito-Tempol, Mito-CP and Mito-
CTP), MitoEbselen, MitoB, Mito-αToc. Among those compounds, Mito-
SOX™ Red bears dihydroethidium as a redox-active unit, which reacts
stoichiometrically with O2−, and is thus often used as a mechanistic
tool to provide evidence that O2− has indeed been involved in a
mitochondrially-based disorder. Caution needs to be exercised because
modulatory effect of MitoSOX™ Red (but not SOX – dihydroethydium –
in its own right) on cellular bioenergetics has recently been observed
[103]. Other compounds, which were shown beneﬁcial in reducing
oxidative stress, and for which some evidence exists that they reach
the mitochondria, have also been discussed.
11. Abbreviations
AP-1, activator protein-1; bFGF, basic ﬁbroblast growth factor;
BMP-7, bone morphogenic protein-7; CO3–, carbonate radical; DMBA,
7,12-dimethylbenz (a)-anthracene; E1/2, half-wave reduction poten-
tial; EPO, erythropoietin; HClO, hypochlorous acid; HIF-1α, hypoxia
inducible factor-1α; icv, intracerebroventricular; IL-1, interleukin-1,
IL-6, interleukin-6; ip, intraperitoneal; iv, intravenous; MitoQ, mito-
quinone; NF-κB, nuclear factor κB; NHE, normal hydrogen electrode; OH,
hydroxyl radical; O2–, superoxide; ONOO–, peroxynitrite; PBW, partition
between n-butanol and water; POW, partition between n-octanol
andwater; Rf, thin-layer chromatographic retention factor that presents
the ratio between the solvent and compound path in 1:1:8=KNO3(sat):
H2O:CH3CN solvent system; RO2 (RO), lipid peroxyl (alkoxyl) radicals;
ROS, reactive oxygen species; RS, reactive species; SAR, structure-
activity relationship; sc, subcutaneous; SDF-1, stromal cell derived
factor-1; SOD, superoxide dismutase; Sp1, speciﬁcity protein 1; TPA,
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ubisemiquinone; VEGF, vascular endothelial growth factor; charges
in the MnP abbreviations are omitted throughout Figure legends;
MnPs, Mn(III) N-alkylpyridylporphyrins; MnIIIP oxidized (Mn +3
oxidation state) and MnIIP reduced Mn porphyrin (Mn +2
oxidation state), total charge 5+ and 4+ are omitted in text. BBB,
blood brain barrier; MnTPP+, Mn(III) meso-tetrakisphenylporphyrin;
MnTM-2-PyP5+, Mn(III) meso-tetrakis(N-methylpyridinum-2-yl)
porphyrin; MnT-2-PyP+, Mn(III) meso-tetrakis (N-pyridinium-2-yl)
porphyrin; MnTE-2-PyP5+, AEOL10113, FBC-007, Mn(III) meso-
tetrakis(N-ethylpyridinum-2-yl)porphyrin; MnTnHex-2-PyP5+, Mn(III)
meso-tetrakis(N-n-hexylpyridinum-2-yl)porphyrin; MnTnHex-3-PyP5+,
Mn(III) meso-tetrakis(N-n-hexylpyridinum-3-yl)porphyrin; MnTnOct-
2-PyP5+, Mn(III) meso-tetrakis(N-n-octylpyridinum-2-yl)porphyrin;
MnBr8TM-3-PyP4+, Mn(II) β-octabromo-meso-tetrakis(N-methyl-
pyridinum-3-yl)porphyrin; MnCl5TE-2-PyP4+, Mn(II) β-
pentachloro-meso-tetrakis(N-ethylpyridinum-2-yl)porphyrin;
MnTMOHex-3-PyP5+, Mn(III) meso-tetrakis(N-(6′-methoxyhexyl)
pyridinum-3-yl)porphyrin; MnTnBuOE-2-PyP5+ (BMX-001), Mn(III)
meso-tetrakis(N-2′-butoxyethylpyridinium-2-yl)porphyrin; MnTDE-2-
ImP5+ (AEOL10150), Mn(III) meso-tetrakis(N, N′-diethylimidazolium-
2-yl)porphyrin; MnMImP3P2+, Mn(III) 5,10,15-trisimidazolium-20-
mono(N, N′-dimethylimidazolium-2-yl)porphyrin; MnTBAP3− (also
MnTCPP3− and AEOL10201), Mn(III) meso-tetrakis(4-carboxylatophe-
nyl)porphyrin; MnTM-4-PyP5+, manganese(III) meso-tetrakis(N-
methylpyridinium-4-yl)porphyrin; MnTECP, manganese meso-tetrakis-
(ethoxycarbonyl) porphyrin; FeTE-2-PyP(OH)4+, Fe(III) monohydroxo
meso-tetrakis(N-ethylpyridinum-2-yl)porphyrin.
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